Teva Completes First Year of Shipments of Adenovirus Vaccine to the United States Military
Teva Select Brands and the United States Military have completed the first year of shipments of Adenovirus vaccine for military recruits. Respiratory infections caused by certain types of Adenovirus can spread rapidly among recruits undergoing basic training. Since the re-introduction of the vaccine in October of 2011, over 200,000 military men and women have been protected by the vaccine.
“Since the program began last year, combined data from the training installations indicates that the vaccine has reduced the incidence of febrile respiratory illness by over 75% and essentially eliminated the threat posed by adenovirus types 4 and 7,” said Clifford E. Snyder, Jr. JD, PhD, adenovirus vaccine product manager at the U.S. Army Medical Materiel Development Activity.
The vaccine approved by the FDA in March of 2011 for Military Use Only, can help save millions of dollars in lost training time, wages and health care costs, while protecting the health of the recruits. “We are proud of our partnership with the Military and we hope to continue supplying this important vaccine as long as it is needed by our Government,” said Michael G. McHugh, General Manager and Vice President of Teva Select Brands.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.